Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
melrilimab 70 milligram · 1 trial · 2 indications
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other situations which involve medical or scientific judgment.
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847. Pharmacokinetic Population consisted of all randomized participants who received at least one dose of study treatment, and for whom at least one pharmacokinetic sample was obtained, analyzed and measurable.
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.
| Arm | Type | Description |
|---|---|---|
| Participants receiving melrilimab (GSK3772847) 70 milligram (mg) | EXPERIMENTAL | Participants will receive a single dose of melrilimab (GSK3772847) 70 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP). |
| Participants receiving melrilimab (GSK3772847) 140 milligram (mg) | EXPERIMENTAL | Participants will receive a single dose of melrilimab (GSK3772847) 140 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP). |
| Participants receiving Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo subcutaneously (SC) injection by an health care professional (HCP). |
| Name | Type | Description |
|---|---|---|
| melrilimab (GSK3772847) 70 milligram (mg) | BIOLOGICAL | melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial. |
| melrilimab (GSK3772847) 140 milligram (mg) | BIOLOGICAL | Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL) |
| Placebo | OTHER | Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial. |
Inclusion Criteria: * Participants age in between 18 to 65 years, at the time of signing the informed consent. * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A participant with a c...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Melrilimab 70 milligram is a monoclonal antibody developed by GSK plc under the code GSK3772847. It is an investigational therapy being studied in asthma. The 70 milligram dose refers to a specific strength evaluated in clinical research. It has been tested in a Phase 1 trial in healthy participants.
Melrilimab 70 milligram is being developed for the treatment of asthma. It is an investigational monoclonal antibody, and its safety, tolerability, pharmacokinetics, and pharmacodynamics have been evaluated in a Phase 1 study that included healthy volunteers and participants with asthma.
Melrilimab 70 milligram is made by GSK plc, which trades on the New York Stock Exchange under the ticker GSK. GSK is the developer of the monoclonal antibody, also known as GSK3772847, and is responsible for its clinical development in asthma.
Melrilimab 70 milligram is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved by the FDA. The Phase 1 trial evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics has been completed.
Melrilimab 70 milligram has been studied in one completed Phase 1 clinical trial, NCT04366349. This trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of melrilimab (GSK3772847) in healthy participants and involved 65 participants in the United States.
Yes, melrilimab 70 milligram is the same as melrilimab (GSK3772847) 70 milligram. GSK3772847 is the development code for melrilimab, and the 70 milligram designation refers to the dose strength. Both names refer to the same investigational monoclonal antibody developed by GSK plc.